Our multivariable analysis revealed that five independent baseline factors (neutrophilia, thrombocytosis, hypoalbuminemia, body mass index <30 kg/m2, and the absence of lung metastasis) were able to predict individual outcome not only in patients with KRAS+/TP53+ mutant cancer who had received therapy in a phase I clinical trial, but also in those who had not received therapy. The gene discussed is KRAS; the disease is Hypoalbuminemia.